Morning Workshop A:
Utilising Imaging to Maximise the Potential of Advanced Oncology Portfolios
Molecular imaging has the potential to be a revealing tool for the diagnosis and monitoring of various cancers in the clinic. Similarly it has potential to accelerate oncology clinical trials, establish new patient selection strategies and serve as a biomarker of treatment response, potentially opening new avenues to recently validated targets. Optimise your usage of cutting edge molecular imaging technology to accelerate your pipeline development.
Join this workshop to discuss:
- Drug Repurposing using Radiochemistry
- Pre-clinical imaging for drug validation
- Collaborative efforts in radiochemistry Bringing results to the clinic
Tom Christian Holm Anderson
PI 180 ºN, the Norwegian Nuclear Medicine Consortium Chief Radiochemist & Production Manager Centre for Nuclear Medicine & PET Department of Radiology
Haukeland University Hospital
Director Of The Pre-Clinical Unit
University of Tromsø - The Arctic University of Norway (UiT)
Afternoon Workshop B:
Conducting Safe & Effective Clinical Trials with Theranostic Radiopharmaceuticals in Cancer
In this workshop we will be bringing together specialists who have been on the front lines of clinical trials with leading scientists in radiopharmaceuticals. Discuss how to effectively work across disciplines – collaborating with oncologists and radiobiologists to advance radiopharmaceuticals.
Join your peers to start a dialogue over the potential of radiopharmacy in cancer and how this can be achieved through careful clinical trial design, planning and execution.
Crossing this precipice is the first step to widening the acceptance of radiopharmaceuticals as an advance tool in oncology.
Director, Radiological Physics Division, Professor of Radiology & Radiological Science
Johns Hopkins Medicine
Professor of Medicine Medical Director
Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research